STAT3

Jun 11, 2020

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

Jun 11, 2020

Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California

Jun 02, 2020

Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment